Skip to main content
SpringerLink
Log in
Book cover

Exercise and Sports Pulmonology pp 97–110Cite as

Exercise in Interstitial Lung Diseases

  • Chapter
  • First Online:

Abstract

Interstitial lung diseases (ILDs) represent a group of diverse chronic lung conditions characterized by scaring, inflammation, and restrictive pathophysiology. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILDs and is associated with severe signs and symptoms, exercise intolerance, impaired quality of life, and poor prognosis. Exercise training has been shown to be a safe and effective treatment in a variety of ILDs including IPF. Exercise training improves exercise tolerance, functional capacity, dyspnea, and quality of life both in patients with ILDs and IPF. Higher exercise capacity and physical activity levels have been demonstrated to be associated with better survival and enhanced quality of life. The optimal training modalities and the underlining mechanisms with respect to outcome improvements are yet to be well characterized and require further investigation. The existing evidence supports the clinical benefits of exercise in patients with ILDs and thus provides good justification to recommend exercise training as part of standard care for ILDs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kebbe J, Abdo T. Interstitial lung disease: the diagnostic role of bronchoscopy. J Thorac Dis. 2017;9(Suppl 10):S996–S1010.

    PubMed  PubMed Central  Google Scholar 

  2. Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration. 2015;89(2):89–99.

    PubMed  Google Scholar 

  3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

    PubMed  PubMed Central  Google Scholar 

  4. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176(3):277–84.

    PubMed  Google Scholar 

  5. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8.

    PubMed  PubMed Central  Google Scholar 

  6. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.

    Google Scholar 

  7. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med. 2008;102(12):1675–80.

    PubMed  PubMed Central  Google Scholar 

  8. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005;60(7):588–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    PubMed  Google Scholar 

  10. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–9.

    CAS  PubMed  Google Scholar 

  11. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    PubMed  Google Scholar 

  12. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;10:CD006322.

    Google Scholar 

  13. Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manag. 2012;43(4):771–82.

    Google Scholar 

  14. Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101–9.

    PubMed  Google Scholar 

  15. Kozu R, Jenkins S, Senjyu H. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16(8):1196–202.

    PubMed  Google Scholar 

  16. Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clin Chest Med. 2004;25(3):435–53.. v

    PubMed  Google Scholar 

  17. Holland AE. Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7(2):101–11.

    PubMed  Google Scholar 

  18. Spruit MA, Singh SJ, Garvey C, Zuwallack R, Nici L, Rochester C, et al. An official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.

    PubMed  Google Scholar 

  19. American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–77.

    Google Scholar 

  20. Arena R, Sietsema KE. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. Circulation. 2011;123(6):668–80.

    PubMed  Google Scholar 

  21. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191–225.

    PubMed  Google Scholar 

  22. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261–74.

    PubMed  PubMed Central  Google Scholar 

  23. American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription, vol. xxiv. 9th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014. p. 456.

    Google Scholar 

  24. Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873–934.

    Article  PubMed  Google Scholar 

  25. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(5):1421–9.

    PubMed  Google Scholar 

  26. Kawut SM, O’Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med. 2005;99(11):1431–9.

    PubMed  Google Scholar 

  27. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(6):659–64.

    PubMed  PubMed Central  Google Scholar 

  28. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103(1):117–23.

    PubMed  Google Scholar 

  29. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084–90.

    PubMed  Google Scholar 

  30. Vainshelboim B, Kramer MR, Izhakian S, Lima RM, Oliveira J. Physical activity and exertional desaturation are associated with mortality in idiopathic pulmonary fibrosis. J Clin Med. 2016;5(8):E73.

    PubMed  Google Scholar 

  31. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5):402–7.

    PubMed  Google Scholar 

  32. Triantafillidou C, Manali E, Lyberopoulos P, Kolilekas L, Kagouridis K, Gyftopoulos S, et al. The role of cardiopulmonary exercise test in IPF prognosis. Pulm Med. 2013;2013:514817.

    PubMed  PubMed Central  Google Scholar 

  33. Vainshelboim B, Oliveira J, Fox BD, Kramer MR. The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis. Respir Care. 2016;61(8):1100–9.

    PubMed  Google Scholar 

  34. Layton AM, Armstrong HF, Kim HP, Meza KS, D’Ovidio F, Arcasoy SM. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med. 2017;126:59–67.

    PubMed  Google Scholar 

  35. Vainshelboim B, Oliveira J, Izhakian S, Unterman A, Kramer MR. Lifestyle behaviors and clinical outcomes in idiopathic pulmonary fibrosis. Respiration. 2018;95(1):27–34.

    PubMed  Google Scholar 

  36. Vainshelboim B, Oliveira J, Fox BD, Adir Y, Ollech JE, Kramer MR. Physiological profile and limitations in exercise in idiopathic pulmonary fibrosis. J Cardiopulm Rehabil Prev. 2016;36(4):270–8.

    PubMed  Google Scholar 

  37. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.

    Google Scholar 

  38. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–46.

    PubMed  Google Scholar 

  39. Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447–78.

    PubMed  Google Scholar 

  40. Vainshelboim B, Fox BD, Oliveira J, Kramer MR. Exercise training in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016;10(1):69–77.

    CAS  PubMed  Google Scholar 

  41. Tuppin MP, Paratz JD, Chang AT, Seale HE, Walsh JR, Kermeeen FD, et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant. 2008;27(7):729–34.

    PubMed  Google Scholar 

  42. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol. 2006;57(Suppl 4):139–48.

    PubMed  Google Scholar 

  43. Ozalevli S, Karaali HK, Ilgin D, Ucan ES. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. 2010;5(1):31–7.

    PubMed  PubMed Central  Google Scholar 

  44. Swigris JJ, Fairclough DL, Morrison M, Make B, Kozora E, Brown KK, et al. Beneficial effects of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56(6):783–9.

    PubMed  Google Scholar 

  45. Rammaert B, Leroy S, Cavestri B, Wallaert B, Grosbois JM. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. Rev Mal Respir. 2011;28(7):e52–7.

    CAS  PubMed  Google Scholar 

  46. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135(2):442–7.

    PubMed  Google Scholar 

  47. Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schonheit-Kenn U, Neurohr C, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2013;42(2):444–53.

    PubMed  Google Scholar 

  48. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–9.

    PubMed  Google Scholar 

  49. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–54.

    CAS  PubMed  Google Scholar 

  50. Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014;108(1):203–10.

    PubMed  Google Scholar 

  51. Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 2017;72(7):610–9.

    PubMed  Google Scholar 

  52. Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I, et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med. 2017;17(1):130.

    PubMed  PubMed Central  Google Scholar 

  53. Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. Respir Care. 2014;59(7):1108–15.

    PubMed  Google Scholar 

  54. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration. 2014;88(5):378–88.

    PubMed  Google Scholar 

  55. Jackson RM, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014;192:367.

    CAS  PubMed  Google Scholar 

  56. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008;4:CD006322.

    Google Scholar 

  57. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. 6-minute walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9):1231–7.

    PubMed  Google Scholar 

  58. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334–59.

    PubMed  Google Scholar 

  59. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem GJ, et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. Med Sci Sports Exerc. 2009;41(7):1510–30.

    PubMed  Google Scholar 

  60. World Health Organization. Global recommendations on physical activity for health. 2010. http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf.

  61. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380(9838):247–57.

    PubMed  Google Scholar 

  62. Nakayama M, Bando M, Araki K, Sekine T, Kurosaki F, Sawata T, et al. Physical activity in patients with idiopathic pulmonary fibrosis. Respirology. 2015;20(4):640–6.

    PubMed  Google Scholar 

  63. Wallaert B, Monge E, Le Rouzic O, Wemeau-Stervinou L, Salleron J, Grosbois JM. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest. 2013;144(5):1652–8.

    PubMed  Google Scholar 

  64. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, et al. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med. 2017;17(1):104.

    PubMed  PubMed Central  Google Scholar 

  65. Vainshelboim B, Fox BD, Kramer MR, Izhakian S, Gershman E, Oliveira J. Short-term improvement in physical activity and body composition after supervised exercise training program in idiopathic pulmonary fibrosis. Arch Phys Med Rehabil. 2016;97(5):788–97.

    PubMed  Google Scholar 

  66. Gaunaurd IA, Gomez-Marin OW, Ramos CF, Sol CM, Cohen MI, Cahalin LP, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014;59(12):1872–9.

    PubMed  Google Scholar 

  67. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et al. Amount of time spent in sedentary behaviors in the United States, 2003–2004. Am J Epidemiol. 2008;167(7):875–81.

    PubMed  Google Scholar 

  68. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. Ann Intern Med. 2015;162(2):123–32.

    PubMed  Google Scholar 

  69. Bouchard C, Blair SN, Katzmarzyk PT. Less sitting, more physical activity, or higher fitness? Mayo Clin Proc. 2015;90(11):1533–40.

    PubMed  Google Scholar 

  70. Atkins C, Baxter M, Jones A, Wilson A. Measuring sedentary behaviors in patients with idiopathic pulmonary fibrosis using wrist-worn accelerometers. Clin Respir J. 2018;12(2):746–53.

    CAS  PubMed  Google Scholar 

  71. Leuchte HH, Mernitz P, Baezner C, Baumgartner RA, von Wulffen W, Neurohr C, et al. Self-report daily life activity as a prognostic marker of idiopathic pulmonary fibrosis. Respiration. 2015;90(6):460–7.

    PubMed  Google Scholar 

  72. Kenney WL, Wilmore JH, Costill DL. Physiology of sport and exercise, vol. xvii. 5th ed. Champaign, IL: Human Kinetics; 2012. p. 621.

    Google Scholar 

  73. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. Circulation. 2016;134(24):e653–e99.

    PubMed  Google Scholar 

  74. Kenn K, Gloeckl R, Behr J. Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis—a review. Respiration. 2013;86(2):89–99.

    CAS  PubMed  Google Scholar 

  75. Manali ED, Lyberopoulos P, Triantafillidou C, Kolilekas LF, Sotiropoulou C, Milic-Emili J, et al. MRC chronic dyspnea scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med. 2010;10:32.

    PubMed  PubMed Central  Google Scholar 

  76. Keyser RE, Woolstenhulme JG, Chin LM, Nathan SD, Weir NA, Connors G, et al. Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm Rehabil Prev. 2015;35(1):47–55.

    PubMed  PubMed Central  Google Scholar 

  77. Vainshelboim B, Kramer MR, Fox BD, Izhakian S, Sagie A, Oliveira J. Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis. Eur J Phys Rehabil Med. 2017;53(2):209–18.

    PubMed  Google Scholar 

  78. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104(7):1035–41.

    PubMed  Google Scholar 

  79. Nakazawa A, Cox NS, Holland AE. Current best practice in rehabilitation in interstitial lung disease. Ther Adv Respir Dis. 2017;11(2):115–28.

    PubMed  Google Scholar 

  80. Garvey C. Interstitial lung disease and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2010;30(3):141–6.

    PubMed  Google Scholar 

  81. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.

    CAS  PubMed  Google Scholar 

  82. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration. 2011;81(3):196–205.

    PubMed  Google Scholar 

  83. Holland AE, Dowman L, Fiore J Jr, Brazzale D, Hill CJ, McDonald CF. Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test. BMC Pulm Med. 2014;14:136.

    PubMed  PubMed Central  Google Scholar 

  84. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007;131(5 Suppl):4S–42S.

    PubMed  Google Scholar 

  85. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390–413.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Master of Cancer Care Program, School of Health Sciences, Saint Francis University, Loretto, PA, USA

    Baruch Vainshelboim

  2. Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel

    Baruch Vainshelboim

  3. Faculty of Sport, Research Center in Physical Activity, Health and Leisure (CIAFEL), University of Porto, Porto, Portugal

    Baruch Vainshelboim

Authors
  1. Baruch Vainshelboim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Centre for Exercise and Sport Science, University of Ferrara, Ferrara, Italy

    Annalisa Cogo

  2. National Heart and Lung Institute, Imperial College London, London, UK

    Matteo Bonini

  3. Internal medicine Department, Ospedale Civile di Alghero, ASSL Sassari, ATS Sardegna, Alghero, Italy

    Paolo Onorati

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vainshelboim, B. (2019). Exercise in Interstitial Lung Diseases. In: Cogo, A., Bonini, M., Onorati, P. (eds) Exercise and Sports Pulmonology. Springer, Cham. https://doi.org/10.1007/978-3-030-05258-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05258-4_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-05257-7

  • Online ISBN: 978-3-030-05258-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation